D-Pharm LTD., a biopharmaceutical company, designs and develops drugs for the treatment of brain disorders in Israel and internationally. Its products under advanced clinical development include DP-b99, a pivotal Phase III trial ongoing product in acute ischemic stroke patients; and DP-VPA, a Phase II trial completed product in epilepsy patients. The DP-b99’s therapeutic applications also include the treatment of traumatic brain injury and diminishing the risk of brain damage associated with coronary artery bypass graft surgery; and DP-VPA’s therapeutic applications comprise the treatment of bipolar disorder and prophylactic therapy in migraine patients. The company also has a pipeline of pre-clinical candidates for treatment of neuro-degenerative diseases, other CNS disorders, and cancer. Its pre-clinical candidates comprise DP-460 for the treatment of Alzheimer’s disease; DP-71 for the treatment of psoriasis; and DP-388 to treat pancreatic cancer. The company’s platform technologies, Membrane Activated Chelators and Regulated Activation of Prodrugs, enable the design of drug-candidates; and LipidoMimetix technology enables the design of analogues that mimic bioactive lipids, facilitating their use as safe and effective therapeutics. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel.
d-pharm ltd (DPRM:Tel Aviv)
Kiryat Weizmann Science Park
PO Box 2313
Phone: 972 8 9385100
Fax: 972 8 9300795www.dpharm.com
|No competitor information is available for DPRM.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Post a JobJobs
- Pittsburgh, PA | Carnegie Museums of PittsburghPosted: Dec 09
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA |Posted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26
Sponsored Financial Commentaries
To contact D-PHARM LTD, please visit www.dpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.